Thomas Reinke

Health plans have another option to consider for improving medication outcomes

Thomas Reinke

Health plans have not really bought into pharmacists’ claims that they can do more than pour, count, lick, and stick and that their role should be expanded into medication management or other aspects of patient care. Yet there is mounting pressure for health plans to do more to improve medication outcomes and to demonstrate value for pharmacy benefits. Thus, health plans face the challenge of determining if, where, and how they are going to improve pharmaceutical care.

Embedded pharmacists

Several models of expanded pharmacy practice have been tested. One model — embedding pharmacists in patient-centered medical homes — has recently received increased attention and support.

The idea is that pharmacists can have the greatest effect on medication outcomes when they are part of a care team.

“This model establishes an essential relationship between the patient, the primary care provider, and the pharmacist,” says Marie Smith, PharmD, a pharmacy professor at the University of Connecticut. “Pharmacists have relationships with patients and with physicians or nurses, but often not simultaneously.”

She described the role of pharmacists in medical homes in a recent Health Affairs article.

The core services of pharmacists in medical homes are:

  • Review of current drug usage
  • Assessment of the efficacy of, and the patient’s adherence to, each medication
  • Development of a medication care plan
  • Education of the patient and care team about that plan

These activities clearly define the pharmacist’s role in a team approach, as opposed to other expanded-practice activities such as immunizations.

Smith explains that there is a powerful advantage for pharmacists when there is direct contact with patients and the health care team. “How do you build trust with patients and physicians? It’s through visibility and direct contact. For patients, when a relationship is established, patients will share valuable information they may not give to their doctors.

“Among health care professionals, immediate availability and the opportunity to see how you function are important for good collaborative relationships.” The evidence for having pharmacists in medical homes includes programs where there has been a direct effect on improving medication outcomes for chronic conditions. One of these programs was the Asheville Project where pharmacists improved blood pressure control and lowered cholesterol, cutting downstream medical costs and generating a return on investment of 12.6 percent.

Major hurdles

There are at least two significant barriers to this approach. The first is building and proving the business case — financial feasibility. Direct fee-for-service payment from private health plans is rare and would have to be in the range of $2 to $3 per minute. Capitation and per-patient care coordination fees have been suggested as alternatives. But payers have been reluctant to create a payment methodology for their services.

The second hurdle is having all states adopt reasonably uniform pharmacy practice regulations to govern the services of pharmacists in community-based settings.

Smith says that in spite of these hurdles, some provider organizations, such as Minnesota’s Fairview Health Services, have moved ahead by integrating pharmacists into their practice and clinic sites.

Contact the author at

The embedded pharmacist model ”establishes an essential relationship between the patient, the primary care provider, and the pharmacist,” says Marie Smith, PharmD, a pharmacy professor at the University of Connecticut.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.